Item 8.01 Other Events.



On October 6, 2020, BeiGene, Ltd. ("BeiGene") and BioAtla, Inc., a global
clinical-stage biotechnology company focused on the development of Conditionally
Active Biologic (CAB) protein therapeutics ("BioAtla"), issued a joint press
release announcing that the two companies have revised their previous global
co-development and commercialization agreement for BioAtla's investigational CAB
CTLA-4 antibody, BA3071. The previous agreement from April 2019 now becomes a
global licensing agreement for BA3071, pursuant to which BeiGene will hold an
exclusive global license to BA3071 and will be solely responsible for its global
clinical development and commercialization and have the right to receive all
profits on any future sales, net of royalty payments to BioAtla. The full text
of this press release is filed as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d)  Exhibits.

Exhibit No.                                                                                       Description
99.1                Press Release titled "BioAtla and BeiGene Revise Global Development and
                    Commercialization Agreement for Novel Conditionally

Active Biologic CTLA-4


                    Candidate BA3071" dated October 6, 2020.
104                 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses